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1. Introduction
   Streptozotocin (STZ) induce production of oxygen radicals 
in the body that cause pancreatic injury responsible for the 
decrease in the insulin production leading to increase in 
blood sugar levels (hyperglycaemia). The hyperglycaemia 
in turn leads to increase in production of reactive oxygen 
species (ROS) which represent the main mediators of 
cellular injury. Increased in production of ROS impaired 
antioxidant defense systems and the lipid peroxidation 
induction which represent the main mechanism in many 
types of diseases, including the renal, cardiovascular 
diseases, cancer, the aging process and ROS mediated 
diabetic pathogenesis[1,2].
  Cos in ium f enes t ra tum  ( C.  f enes t ra tum )  Co lebr . 
(Menispermaceae), is a woody climber found in India and 
Southeast Asia. The stem bark is widely used in traditional 
medicine. The infusion and tincture preparation of the 
stem bark is used in the traditional Ayurvedic system 
for the treatment of diabetes mellitus[3,4]. In the Siddah 
system of medicine, the powdered stem of the plant 
is used to treat diabetic patients[5]. Protoberberine 
alkaloids including berberine have been reported as 
the main constituents of the stem of C. fenestratum[6,7]. 
Tertiary alkaloids berlambine, dihydroberlambine and 
noroxyhydrastinine have also been isolated from the 
roots[8]. 
   In our previous studies, the stem bark extract of C. 
fenestratum showed hypoglycaemic effect on streptozotocin 
(STZ)-induced diabetic rats[9]. Streptozotocin induced 
acute hyperglycaemia affects the functioning of the liver 
and kidneys due to the excess production of reactive 
oxygen species. Therefore, the aim of the present study 
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was to evaluate the effect of standardized dichloromethane 
(DCM) extract of C. fenestratum stem bark on liver and 
kidney function parameters in streptozotocin (STZ)-
induced diabetic rats.
2. Materials and methods 
2.1. Chemicals 
   Dichloromethane, methanol (HPLC grade) tragacanth 
powder and Tween 40 were obtained from Merck, 
(Darmstadt, Germany). Streptozotocin and tolbutamide were 
purchased from Sigma-Aldrich, USA. All others chemicals 
were of analytical or HPLC grade.
 
2.2. Plant material
   C. fenestratum (20 kg) were obtained from Laboratory 
of Natural Products (NATPRO), Institute of Bioscience, 
University Putra Malaysia (UPM), Selangor, Malaysia. The 
plant was identified by Mr. Shamsul Khamis from NATPRO, 
UPM, Selangor, Malaysia. A voucher specimen is kept in 
the Institute for future reference.
2.3. Preparation and partial purification of extract
   The plant material (stem) was air-dried at 25 曟 for a 
week. The dried stem was cut into pieces and ground into 
powder form using a miller. Dried ground stem powder 
(1 kg) was extracted with DCM (4 L) for 48 h at room 
temperature. 
   The extract was filtered through Whatman filter paper 
and concentrated using rotary evaporator at 37 曟 to yield 
a crude DCM extract (24.5 g). The DCM extract was partially 
purified using column chromatography technique with 
silica gel as stationary phase and methanol as mobile 
phase. Eluent was concentrated with rotary evaporator 
until dry at temperature 37 曟 and stored at -20 曟 until 
analysis.
2.4. HPLC analysis 
   Beberine (BE) was used as a standard marker compound. 
The separation and quantification of BE from the partially 
purified extract of C. fenestratum stem was performed by 
using Agilent 1200 HPLC System equipped with G1311A 
quaternary pump with G1322A degasser and G1315D diode 
array detector (DAD). The chromatographic separation 
was achieved with ODS column, Chromolith, RP-18e, 
100 mm 伊 4.6 mm from Merck (Darmstadt, Germany). The 
mobile phase comprising of HPLC grade methanol and 
deionized water (90:10, v/v) with a flow rate of 0.5 mL/min 
and a column temperature of 25 曟. The mobile phase 
was filtered under vacuum through 0.45 毺m pores nylon 
filter membrane. UV detection was carried out at 254 nm. 
A volume of 20 毺L of sample solution was injected each 
time. 
   Authentic BE standard solution and partially purified 
extract solution (1 mg/mL) were prepared in HPLC grade 
methanol.  Standard solutions of BE in the range of 50-
500 毺g/mL were prepared and injected into HPLC system 
to establish a calibration curve. Peak area versus marker 
concentration was subjected to least square linear 
regression analysis and the slope, intercept and correlation 
coefficient for the calibration curve were determined. 
    The quantity of BE from the extract was expressed as 
%w/w. All measurements were performed in triplicates. The 
sample solutions and standard solutions were filtered using 
0.45 毺m syringe filter (Merck, Darmstadt). 
2.5. Animals
   Albino Wistar rats of both sexes weighting (180-200 g) 
were purchased from Institute of Medical Research (IMR), 
Kuala Lumpur, Malaysia. They were housed in standard 
metal cages at (26 依 2) 曟 and maintained under standard 
12 h light/12 h dark cycle throughout the duration of the 
study. 
   All animals were given access to food and water ad 
libitum. They were deprived of food but not water before 
the commencement of the experiment. The drugs and test 
substances were administered orally. All the procedures 
involved animal testing in this study were reviewed and 
approved by Faculty Research Ethics Committee.
2.6. Toxicity studies
   Rats of either sex (n=6), starved overnight were orally fed 
with SFCE at a dose of 5 000 mg/kg body weight for 15 d. 
The rats were observed for 4 h for behavioral, neurological 
and autonomic profiles. The animals were observed for 
lethality (death) after a period of 72 h.
2.7. Induction of hyperglycaemia in rats
   The initial bodyweight and blood glucose level of 
experimental rats were measured and noted. The rats 
were then fasted overnight for at least 12 h prior to STZ 
induction[10]. 
   The induction of diabetes was performed via a single 
intraperitoneal (i.p.) injection whereby each rat received a 
dosage of 65 mg/kg bodyweight STZ. 
   The blood glucose level and the bodyweight of the 
rats were assessed 72 h post-STZ injection to confirm 
hyperglycaemia and only rats with elevated blood glucose 
levels of above 11.0 mmol/L or 200 mg/dL were used for 
this study. All the rats had free access to water and food 
after the administration of STZ.
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2.8. Study design, treatment and measurement of blood 
glucose level of experimental rats
   In the experiment, 20 rats (15 diabetic rats, 5 normal rats) 
were divided into four groups of 5 rats each (n = 5).
Group I: Normal rats treated with 0.9% saline.
Group II: STZ-induced diabetic rats administered with 
0.9% saline.
Group III: STZ-induced diabetic rats administered with 
tolbutamide (100 mg/kg).
Group IV: STZ-induced diabetic rats administered with 
SFCE (100 mg/kg).
   Before the commencement of the treatments, blood 
samples for glucose determination were obtained from 
the tail tip of the 12 h fasted rats on day-0 (before STZ 
administration) and day-3 (72 h post STZ administration). 
The blood glucose levels of the rats were determined 
immediately by using a quantitative glucose meter, 
Accutrend襆 GCT and Accutrend襆 Glucose test strips coded 
852 (Roche Diagnostics, Germany). 
   Bodyweights of all the experimental rats were also 
measured on day-0 (before STZ administration) and day-3 
(72 h post STZ administration).  Diabetic rats in negative 
control group (Group II) and positive control group (Group 
III) were administered with 0.9% saline and 100 mg/kg 
tolbutamide, respectively. 
   The diabetic rats of the remaining group (Group IV) were 
administered with 100 mg/kg of SCFE. Each drug was 
administered orally once a day for 15 d. Blood samples for 
glucose determination were obtained from the tail tip of 
the diabetic rats on day 1, 5, 10 and 15 of the treatment. 
Bodyweights of all the experimental rats were also 
measured on day 1, 5, 10 and 15 of the treatment.
2.9. Liver and kidney functions test
   After the determination of glucose and body weight on 
the 15 d, the rats were anaesthetized with diethyl-ether 
vapour and blood was obtained by cardiac puncture. 
Blood was quickly transferred to blood collection tubes 
containing heparin and the tubes were placed in ice and 
sent to UCSI University Path Lab (Kuala Lumpur, Malaysia) 
for liver and kidney function analysis. 
   The following parameters were estimated total white 
blood cells (WBC) count, alkaline phosphatase (ALP), blood 
urea nitrogen (BUN) and creatinine. The liver function 
test was analysed by using Roche Cobas C311 chemistry 
analyzer (Roche, Switzerland) and the total WBC count 
was analysed by using Abbot Cell-DYN 3200 hematology 
analyzer (Abbott Laboratories, USA).
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Figure 1. (A) Chemical structure of berberine; (B) HPLC/DAD profile of dichlomethane extract of C. fenestratum at 254 nm. Insert shows UV 
spectra of berberine component.
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 2.10. Statistical analysis
   Statistical significance was assessed using one-way 
analysis of variance (ANOVA) and Dunnett test to compare 
the data. Probability (P) values of less than 0.05 were 
considered significant difference between means. All 
values are presented as means 依 standard error the mean 
(SEM).
3. Results 
3.1. HPLC Analysis
   Figure 1 shows a typical HPLC chromatogram of the 
extract. The identification of BE was based on comparison 
of retention times and UV spectra of peak of BE standard 
with the corresponding peak in the sample chromatogram. 
Quantitation was performed on the basis of linear 
calibration plots of the UV absorption peak area at 254 
nm against concentration. Linear correlation between the 
peak area and concentrations gave correlation coefficient 
of 0.999 which indicates a good linearity. The retention 
time (tr) for BE was 10.94 min. The quantity of BE from the 
extract was found to be 2.09% w/w. 
3.2. Acute toxicity studies
   Rats treated orally with SCFE (5 000 mg/kg body weight) 
showed no signs and symptoms of toxicity over the period 
of treatment (14 d). There was no abnormality in any of the 
organs indicating the C. fenestratum extract is not toxic. 
No significant difference was observed in the relative 
organ weights, body weight gain, food intake and water 
consumption between SFCE treatment groups and control 
group. None of the treated rats died during the period of 
observation after the administration of SCFE. 
3.3. Effect of extract on bodyweight and blood glucose levels 
   Figures 2 and 3 show the effect of treatment of SCFE on 
on body weights and blood glucose levels of experimental 
rats. The bodyweights of  rats showed significant decrease 
72 h post-STZ induction compared to prior diabetes 
induction by STZ (day 0). The fasting blood glucose levels 
of the experimental rats were determined before induction 
of diabetes by STZ at day-0 and day-3 (72 h) post-STZ 
induction. It was observed that STZ administration at a 
dosage of 65 mg/kg  showed significant increase in blood 
glucose levels 72 h post-STZ induction compared to levels 
prior to diabetes induction (day-0). 
   
Figure 2. Effect of treatment of dichlomethane extract of C. 
fenestratum extract on (A) body weights of STZ-induced diabetic rats. 
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Figure 3. Effect of treatment of dichlomethane extract of C. 
fenestratum extract on blood glucose levels of STZ-induced diabetic 
rats. 
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   Oral administration of tolbutamide (100 mg/kg) and 
SCFE (100 mg/kg) to the STZ-induced diabetic rats 
showed significant decrease in blood glucose levels and 
significant increase in bodyweights. Saline did not show 
significant reduction in blood glucose levels and reversal 
of bodyweights of diabetic rats during the 15 d treatment. 
The extract significantly (P<0.05) reduced blood glucose 
Table 1.
Effect of 15 days treatment of C. fenestratum extract on biochemical parameters in normal and STZ induced diabetic.
Groups (n=5) Total WBC (伊109/L)
Alkaline phosphate 
(ALP) (IU/L)
Creatinine (毺mol/L)
Blood urea nitrogen  
(BUM) (mmol/L)
Normal control 9.9 依 0.6 131.7 依 2.4 55.0 依 0.4   4.9 依 0.3
Diabetic control 5.9 依 0.5 938.7 依 4.8 64.7 依 1.2 12.7 依 0.5
Diabetic + tolbutamide (100 mg/kg)   7.1 依 0.4*     604.8 依 5.4**   54.6 依 0.9*     8.3 依 0.5*
Diabetic + SCFE    (100 mg/kg)   7.8 依 0.6*     641.5 依 6.1**   60.3 依 0.6*   10.3 依 0.4*
Normal rats were administered with 0.9% saline. Diabetic control rats were administered with 0.9% saline. Each value represents Mean + 
standard error of the mean (SEM) of five rats per group. **P<0.01, *P<0.05, in comparison with diabetic control values.
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levels of STZ-induced diabetic rats (8.2 依 0.7) mmol/L as 
compared to diabetic control rats (25.0 依 1.8) mmol/L. 
3.4. Effect of extract on biochemical parameters
   The effect of SFCE on total WBC, ALP, creatinine and 
BUN are shown in Table 1. The total WBC was reduced 
in diabetic rats as compared to normal rats. Treatment of 
STZ-induced diabetic rats with SCFE (100 mg/kg b.wt.) 
significantly (P<0.05) increased the WBC values. Treatment 
of STZ-induced diabetic rats with tolbutamide (100 mg/kg 
b.wt.) also elevate the WBC values significantly (P<0.05). 
   Levels of ALP, creatinine and BUN were elevated in 
STZ-induced diabetic rats as compared with the values in 
normal rats. Animals treated with SCFE (100 mg/kg b.wt) 
showed a significant (P<0.01) reduction in the elevated 
levels of ALP, creatinine and BUN. Treatment of STZ-
induced diabetic rats with tolbutamide (100 mg/kg b.wt.), 
significantly (P<0.01) reduced the elevated levels of ALP, 
creatinine and BUN.
4. Discussion 
   The objective of the HPLC part of this study was to 
standardized the DCM extract using BE as a marker before 
administer to the rats. BE was selected as authentic marker 
compound because it has been reported as the major 
bioactive chemical component of C. fenestratum[6,7]. The 
DCM extract was standardized with HPLC to achieve a BE 
concentration of ≥ 2.0 % w/w.  BE is a natural isoquinoline 
alkaloid present in roots and stem bark of Berberis species 
and it has shown a variety of pharmacological activities[11].
   The toxicity studies confirmed that the C. fenestratum 
extract is safe. Administration of SFCE showed no lethality 
or adverse reactions observed at the selected dose during 
the period of observation. All the rats treated with 65 mg/
kg STZ displayed features associated with uncontrolled 
diabetes mellitus, such as elevation of blood glucose levels 
of above 11.1 mmol/L and slight loss in bodyweight 72 h 
post STZ administration[12]. We also observed symptoms 
such as; fatigue, slow movement, increased consumption 
of food (polyphagia), hyperglycemia, and excessive thirst 
(polydipsia). 
   The oral administration of saline did not reduce the blood 
glucose levels or increase in body weights of STZ-induced 
diabetic rats after 15 d treatment. Rather there was an 
elevation of blood glucose and a reduction of bodyweight. 
This shows that there were no hypoglycaemic effects or 
reversal in bodyweight of the diabetic rats exerted by 
the negative control (saline). The orally administration of 
tolbutamide (positive control) at 100 mg/kg to the diabetic 
rats significantly decrease their blood glucose levels 
and slightly increased their body weight after the 15 d 
of treatment. Tolbutamide is an oral anti-hyperglycemic 
agent of the first generation sulfonylurea. Its principal 
action is to increase insulin release from the pancreatic 
毬-cells, reduce serum glucagon levels and closure of 
potassium channels in extra pancreatic tissues to give the 
combined plasma glucose lowering effect[13].   
   The oral administration the SCFE at 100 mg/kg to the 
diabetic rats significantly reduced blood glucose lowering 
levels and increase bodyweights of STZ-induced diabetic 
rats after the 15 d treatment. The reversal of blood glucose 
level and weight loss in diabetic rats treated with SCFE 
suggests that the extract has hypoglycaemic activity. It 
can be suggested that the extract has similar mechanisms 
to that of tolbutamide which promoted glucose uptake by 
enhancing the release of insulin from the pancreatic beta 
cells of the rats. Excessive hepatic glycogenolysis and 
gluconeogenesis is associated with decreased utilization 
of glucose by the tissues of the diabetic rats which caused 
its bodyweight to decrease and its reversal may have been 
the cause for the increase in bodyweights of the diabetic 
rats[14]. The blood glucose lowering effect of the SCFE may 
be ascribed to the alkaloid content including BE which 
was reported to have similar effect to that of metformin[15]. 
Laboratory studies indicate that BE may have at least two 
functions in relation to reducing blood sugar: inhibiting 
absorption of sugars from the intestine and enhancing 
production of insulin[16].   
   Alkaline phosphatase test is used to detect liver damage. 
High ALP values mean that the liver is damaged. Damaged 
liver cells release increased amount of ALP into the blood. 
In this study, high ALP values were observed in diabetic 
control rats as compared to normal rats which reveal liver 
dysfunction in negative control rats. These values were 
significantly reduced in diabetic rats treated with the 
SCFE. The same was observed in rats treated with standard 
drug tolbutamide. Other studies have also reported that 
high ALP values in diabetic rats can be reversed when 
treated with plant extracts and standard drugs that have 
antidiabetic activity[17,18]. The results suggest that the 
extract has the ability to repair liver damage caused by STZ 
in diabetic rats. This effect of the extract can be ascribed to 
the chemical constituents including BE which was reported 
to have hepatoprotective effects on carbon tetrachloride-
induced acute hepatotoxicity in rats[19]. BE administration 
in vivo protected pancreatic islets and serum lipids in 
Nonobese diabetic (NOD) mice[20].  
   Creatinine a metabolite of creatine is generated from 
muscle metabolism. As the kidneys become impaired, the 
creatinine levels in the blood rises due to poor clearance 
by the kidney causing abnormally high levels of creatinine 
which is an indication of possible malfunction or failure of 
the kidneys. Diabetes is one of the most common causes 
of longstanding kidney diseases. This is proved by the 
elevation of creatinine levels in negative control diabetic 
rats compared to normal rats. The creatinine levels were 
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reduced significantly in the diabetic rats treated with the 
SCFE which shows that the treatment reduced the oxidative 
damage to the kidney as well as the diabetic conditions. 
   Blood urea nitrogen (BUN) measures the amount of urea 
nitrogen (waste product of protein metabolism) in the 
blood. The liver forms urea but it is the kidney’s function 
to remove it from the blood stream. So the amount of 
urea nitrogen in the blood can be used as a test of renal 
function, although many other factors can affect the BUN 
values including hydration status and liver failure. When 
kidney functions are impaired, they cause an elevated BUN 
because the kidneys are less able to clear the urea from the 
bloodstream. This condition was observed in the negative 
control rats where BUN values were increased significantly 
compared to normal rats indicating kidney problems. 
These values were significantly reduced in diabetic rats 
treated with SCFE. 
   I n  c o n c l u s i o n ,  1 5  d  t r e a t m e n t  o f  r a t s  w i t h 
dichloromethane extract of C. fenestratum stem bark 
showed no lethality and adverse effects. Standardisation 
of the extract by HPLC confirmed BE as the as the major 
bioactive constituent in the extract. Treatment with the 
standardized extract showed blood glucose lowering 
activity and ability to repair liver and kidney damage 
in STZ-induced diabetic rats. The elevation of liver and 
kidney function parameters in STZ-induced diabetic rats 
were improved by the treatment of the diabetic rats with 
the extract. 
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